Zacks Research Has Negative Forecast for Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG) – Investment analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Neogen in a research report issued to clients and investors on Wednesday, February 12th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.11 per share for the quarter, down from their prior estimate of $0.12. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share.

Neogen (NASDAQ:NEOG) last posted its earnings results on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.12. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm had revenue of $231.30 million during the quarter, compared to the consensus estimate of $227.16 million. During the same quarter last year, the firm earned $0.11 EPS. The firm’s revenue for the quarter was up .7% on a year-over-year basis.

Several other research firms also recently weighed in on NEOG. Piper Sandler reaffirmed a “neutral” rating and issued a $13.00 target price (down from $16.50) on shares of Neogen in a research report on Tuesday, January 21st. Guggenheim initiated coverage on shares of Neogen in a report on Thursday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company.

Neogen Trading Down 0.9 %

Shares of NASDAQ NEOG opened at $9.83 on Monday. The stock has a fifty day simple moving average of $11.78 and a 200-day simple moving average of $14.17. Neogen has a twelve month low of $9.70 and a twelve month high of $18.58. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $2.13 billion, a PE ratio of -4.49 and a beta of 1.23.

Insider Activity at Neogen

In other news, CFO David H. Naemura purchased 14,800 shares of the stock in a transaction on Thursday, January 16th. The stock was bought at an average price of $11.11 per share, for a total transaction of $164,428.00. Following the acquisition, the chief financial officer now directly owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. The trade was a 31.74 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John Edward Adent acquired 23,035 shares of Neogen stock in a transaction dated Thursday, January 16th. The stock was purchased at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the acquisition, the chief executive officer now directly owns 269,164 shares in the company, valued at approximately $2,968,878.92. This represents a 9.36 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Citigroup Inc. lifted its stake in Neogen by 129.1% during the third quarter. Citigroup Inc. now owns 231,833 shares of the company’s stock worth $3,897,000 after purchasing an additional 130,641 shares during the last quarter. American Capital Management Inc. boosted its holdings in shares of Neogen by 36.5% in the 3rd quarter. American Capital Management Inc. now owns 3,414,700 shares of the company’s stock valued at $57,401,000 after buying an additional 913,604 shares in the last quarter. State Street Corp grew its position in shares of Neogen by 3.1% in the 3rd quarter. State Street Corp now owns 7,932,192 shares of the company’s stock valued at $133,340,000 after buying an additional 236,762 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Neogen by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 38,166 shares of the company’s stock worth $642,000 after acquiring an additional 5,804 shares in the last quarter. Finally, Barclays PLC lifted its position in Neogen by 129.8% in the third quarter. Barclays PLC now owns 366,753 shares of the company’s stock valued at $6,165,000 after acquiring an additional 207,160 shares during the last quarter. 96.73% of the stock is owned by institutional investors and hedge funds.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.